Bupropion SR |
Budeprion SR; Wellbutrin SR |
Clinical Trial: Framing Messages for Smoking Cessation with Bupropion - 6
This study is no longer recruiting patients.
Purpose
This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.
| Condition | Treatment or Intervention |
|---|---|
| Tobacco Use Disorder | Drug: Bupropion |
MedlinePlus related topics: Smoking
Study Type: Interventional
Study Design: Treatment, Uncontrolled, Parallel Assignment
Official Title: Framing Messages for Smoking Cessation with Buproprion
Expected Total Enrollment: 252
Study start: September 2000; Study completion: September 2005
Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Exclusion Criteria:
- Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception
- Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality
- Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment
- Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous
- Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six weeks
- History of anorexia nervosa or bulimia
- Previous hypersensitivity to bupropion
- History of alcohol or other drug dependence in the past one year
- History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain injury, substance-induced seizures, etc.)
- Any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule and visit requirements or put the subject at risk
- Sharing home or work environment with current or past participant
- No couples or participants who see each other every day
Location Information
Connecticut
Substance Abuse Treatment Unit, New Haven, Connecticut, 06519, United States
Stephanie O'Malley, Ph.D., Principal Investigator, Substance Abuse Treatment Unit
More Information
Record last reviewed: February 2005
Last Updated: March 1, 2005
Record first received: March 1, 2005
ClinicalTrials.gov Identifier: NCT00104598
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Budeprion SR (Drug Digest)
- Bupropion SR (Drug Digest)

Not Signed In -

